"It's powerful, " says Nicholas Vogelzang , head of the Nevada Cancer Institute.
FORBES: Genentech's Triumph
2.
Even now, says Nicholas Vogelzang , director of the Nevada Cancer Institute, there is a real "paucity" of data for Erbitux, compared with that available for other targeted agents, such as Avastin.